- Merck diabetes drug Sitagliptin was hit by carcinogenic impurities
- CDC relaxes and reiterates its COVID-19 guidance
- How does NOVAVAX solve the dilemma when COVID-19 vaccine sales plummeted by 90%?
- Scientists develop new antibiotic molecule that kills several superbugs
- UK: The polio vaccine booster recommended for all children aged 1 to 9 in London
- Russia has discovered a new COVID-19 “Deltacron” hybrid variant
FDA Suggests to Approve Emergency Use of Pfizer COVID-19 vaccines
FDA Suggests to Approve Emergency Use of Pfizer COVID-19 vaccines. U.S. Food and Drug Administration panel voted for emergency use of Pfizer vaccine.
It was reported on the 11th that an external advisory group of the U.S. Food and Drug Administration (FDA) voted overwhelmingly on December 10 for the emergency use of Pfizer’s COVID-19 vaccine.
According to Reuters, the committee voted 17 to 4 in favor of the vaccine developed by Pfizer and BioNTech to support that the benefits of vaccination outweigh the risks of vaccination for adults 16 and older. One member of the committee abstained.
According to Worldometer’s real-time statistics, the cumulative number of confirmed cases in the United States exceeds 16 million, and the cumulative number of deaths is nearly 300,000.
News This Morning:
FDA reviewed Pfizer’s COVID-19 vaccine today
FDA reviewed Pfizer’s COVID-19 vaccine today. U.S. FDA reviewed Pfizer’s vaccine today , public may get vaccine in 12 days! The U.S. Food and Drug Administration (FDA) announced that a meeting will be held at 9 a.m. on the 10th to discuss whether to urgently authorize the use of the COVID-19 vaccine jointly developed by Pfizer and the German biotech company BioNTech. If it goes well, it can be voted on the same day.
Once the vote is passed, the first batch of vaccines can be shipped directly on the 11th, and the first batch of priority vaccines will be officially opened on the 12th. On the other hand, the FDA confirmed that clinical trials of this vaccine resulted in 6 deaths, of which 2 died of heart attack or stroke, and the cause of death of the remaining subjects is still being confirmed.
Clinical trial caused 6 deaths
According to the Egyptian Independent newspaper, the FDA revealed on the 9th that the COVID-19 vaccine developed by Pfizer and the German biotech company BioNTech has held clinical trials a few days ago, but there have been 6 deaths in the trial. It is understood that one of the deceased suffered from obesity and arteriosclerosis, and he died 3 days after the first dose of the vaccine.
Two other people died of heart attack and stroke, and the cause of death of the remaining subjects is still under investigation. In addition, 3 of the 6 dead were over 55 years old. The FDA has previously confirmed that the vaccine is as effective as 95%, and it has also provided relevant documents to confirm that the vaccine is safe. The FDA will hold a meeting on the morning of the 10th to discuss whether to urgently authorize the use of the vaccine. If the meeting goes smoothly, a vote will be held on the same day, and the vaccine can be opened as soon as 12 days.
British regulatory agency calls for history of severe allergies not to be vaccinated
After the Pfizer crown vaccine was administered in 50 medical institutions in the UK, on the 8th, 2 NHS staff members had allergic reactions due to the vaccination. Although they have recovered after receiving treatment, the exact symptoms and severity of allergies have yet to be confirmed. It is not clear which specific groups will have an allergic reaction to the vaccine. The Medical Regulatory Agency “Medicines and Medical Products Regulatory Agency” (MHRA) earlier stated that people with a history of severe allergies should not be given Pfizer’s COVID-19 vaccine at this stage.